002262 Jiangsu Nhwa Pharmaceutical
- 25.08
- +0.27+1.09%
Jiangsu Nhwa Pharmaceutical News
Express News | Enhua Pharmaceutical: Obtaining an Approval Notice for Supplemental Application for Alfentanyl Hydrochloride Injection
Enhua Pharmaceutical (002262): 1Q24 performance is in line with expectations, focus on the pace of new product release
The 1Q24 results are in line with our expectations. The company announced 1Q24 results: revenue of 1,358 billion yuan, up 15.16% year on year; net profit to mother of 265 million yuan, up 16.65% year on year. The results are in line with our expectations.
Enhua Pharmaceutical (002262): Performance is in line with expectations, optimistic about the release of new products to drive long-term growth
Enhua Pharmaceutical released its 2024 quarterly report. The company achieved operating income of 1,358 billion yuan in the first quarter of 2024, an increase of 15.16% over the previous year; realized net profit of 265 million yuan, an increase of 16.64% over the previous year; deducted
Enhua Pharmaceutical (002262): Steady growth in performance, new products entering the release cycle
Report guide: The company's performance was in line with expectations and showed a steady growth trend. Operational efficiency has improved, and the impact of collection has gradually been clarified. R&D investment has increased, and new products have entered the release cycle. Maintain an “Overweight” rating. Investment Essentials: Maintaining an “Overweight” rating. Dimensions
Express News | Enhua Pharmaceutical: Net profit of 265 million yuan in the first quarter of 2024 increased 16.64% year-on-year
Enhua Pharmaceutical (002262): Excellent performance in the first year of 1Q24
1Q24 performed well. Maintaining the buy-rating company's quarterly report for April 19, 1Q24 achieved revenue of 1,358 million yuan (+15.16% yoy), and net profit of 265 million yuan (+16 million yuan).
Enhua Pharmaceutical (002262): The world has gone through a thousand sails, breaking the waves
Accelerated hospital admission+new products entering the release cycle. It is expected that both valuation and performance will rise. The company is the leading refined hemp company. Currently, the risk of collecting existing products has basically been cleared. With the policy support of accelerated hospital-side access in '24 (nearly 20 provinces have already issued documents requiring medical devices
Enhua Pharmaceutical (002262): Optimistic about new products to drive rapid growth in refined hemp
Key investment points The company's anesthetic products will maintain a high growth rate in 2023. We are optimistic about the company's central nervous system products & follow-up pipeline layout and competitiveness. The impact of stock collection is declining, and high barriers to generic drugs/innovative drugs are being launched one after another to support revenue
Pacific released a research report on April 9 stating that Enhua Pharmaceutical (002262.SZ) was given a purchase rating. The main reasons for the rating include: 1) the steady growth of the narcotics line and the rapid growth of the commercial sector; 2)
Pacific released a research report on April 9 stating that Enhua Pharmaceutical (002262.SZ) was given a purchase rating. The main reasons for the rating include: 1) the steady growth of the narcotics line and the rapid growth of the commercial sector; 2) expenses declined during the period, and the net interest rate remained stable; 3) large single anesthetic analgesia products are expected to be released, contributing to the increase in the introduction of drugs for rare diseases. (Mainichi Keizai Shimbun)
Enhua Pharmaceutical (002262.SZ): The new drug NVX-408 project is still in the pre-clinical research stage
Gelonghui, April 9, 丨 Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “Why has the new drug NVX-408 not progressed?” The company replied that the company's new drug NVX-408 project is still in the pre-clinical research stage.
Enhua Pharmaceutical (002262.SZ): The new drug Oselidine Injection (TRV130) achieved sales of around 18 million yuan last year
Gelonghui, April 9丨Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “How much was the new drug R130 sold last year, and how much was the gross profit?” The company replied that the new drug oselidine injection (TRV130) launched by the company achieved sales of around 18 million yuan last year, and the gross margin was slightly higher than the company's anesthetic products.
Enhua Pharmaceutical (002262.SZ): Gabapentin, risperidone, dexmedetomidine, and olanazepine participated in the collection
Gelonghui, April 9, 丨 Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “What products are currently participating in the collection?” The company replied that gabapentin, risperidone, dexmedetomidine, and olanazepam are equal.
Enhua Pharmaceutical (002262.SZ): Protolin nasal spray, an innovative drug to treat Alzheimer's disease, has completed phase I clinical trials and is expected to conduct phase IIa clinical trials in 2024
Gelonghui, April 9, 丨 Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “What stage has the company reached in the development of innovative drugs for Alzheimer's disease?” The company replied that up to now, the company's innovative drug Protolin nasal spray to treat Alzheimer's disease has completed phase I clinical trials, and it is expected that phase IIa clinical trials will be carried out in 2024.
Enhua Pharmaceutical (002262): Performance meets expectations and strengthens product portfolio treatment plan
Incident Overview The company achieved operating income of 5.04 billion yuan (yoy +17.3%) in 2023; realized net profit attributable to shareholders of listed companies of 1.04 billion yuan (yoy +15.1%), deducting non-net profit 10.
Enhua Pharmaceutical (002262): Steady growth in performance and continuous release of new narcotic products
Core view: The company released its 2023 annual report: the company achieved revenue of 5,042 billion yuan in 2023 (+17.3%, the following are year-on-year ratios); net profit to mother was 1,037 billion yuan (+15.1%); deducted
Nhwa Pharma Gets Nod to Test NH103 Oxalate Tablets
Jiangsu Nhwa Pharmaceutical (SHE:002262) will conduct clinical trials on NH103 oxalate tablets after receiving approval from China's National Medical Products Administration, the company said in its f
Changes in A-shares | Performance is in line with expectations, Enhua Pharmaceutical rose more than 7%
Gelonghui, April 3 | Enhua Pharmaceutical (002262.SZ) bucked the trend and increased by more than 7%. It now reports 23 yuan, with a market value of 23.1 billion yuan. According to news, the company's revenue in '23 was 5,042 billion yuan, up 17.28% year on year; net profit to mother was 1,037 billion yuan, up 15.12% year on year. CICC commented that the company's performance was in line with expectations, focusing on the volume of major core products. Maintain an outperforming industry rating and maintain a target price of 30 yuan.
Enhua Pharmaceutical (002262): Overall performance growth, R&D innovation continues to increase
During the reporting period of the 2023 report, the company achieved operating income of 5,042 billion yuan, an increase of 17.28%; net profit attributable to shareholders of listed companies was 1,037 billion yuan, an increase of 15.12% over the previous year; attributable to shareholders of listed companies
Enhua Pharmaceutical (002262): Performance is in line with expectations, focusing on the release volume of large core products
The 2023 results are in line with our expectations. The company announced its 2023 results: revenue of 5,042 billion yuan, up 17.28% year on year; net profit to mother of 1,037 billion yuan, up 15.12% year on year; deducted non-net profit 10.
Express News | Enhua Pharmaceutical: NH103 obtained the “Drug Clinical Trial Approval Notice”
Analysis
Price Target
No Data
